Evelo biosciences, inc. (EVLO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16
Operating expenses:
Research and development

63,128

39,885

19,957

9,134

General and administrative

23,229

18,218

7,574

3,891

Total operating expenses

86,357

58,103

27,531

13,025

Loss from operations

-86,357

-58,103

-27,531

-13,025

Other (expense) income:
Interest (expense) income, net

1,049

1,563

-215

-287

Other income

26

-406

-301

-

Other expenses

-

-

-

20

Other income, net

1,075

1,157

-516

-307

Loss before income taxes

-85,282

-56,946

-28,047

-

Income tax expense

200

0

0

-

Net loss

-85,472

-56,900

-28,047

-13,332

Convertible preferred stock dividends

0

3,937

6,085

1,645

Net loss attributable to common stockholders

-85,472

-60,883

-34,132

-14,977

Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)

-2.67

-2.78

-9.10

-5.28

Weighted-average number of common shares outstanding, basic and diluted (in shares)

32,031

21,871

3,750

2,834

Comprehensive loss:
Reconciliation of net loss to net loss attributable to common stockholders:
Net loss

-85,472

-56,900

-28,047

-13,332

Net Income (Loss) Attributable to Parent

-85,472

-56,900

-28,047

-

Other comprehensive loss:
Unrealized gain (loss) on investments, net of tax of $0

18

-18

0

0

Comprehensive loss

-85,454

-56,964

-28,047

-13,332